Within the field of health, it is essential to invest in the development of new medicines. The Covid-19 vaccine is one of the best examples because it has worked to prevent millions of deaths. But before arriving with the final population, it is necessary to verify the correct functioning of each drug. That’s what they work for clinical trials and now Mexico is guaranteed its participation for the next few years.
In this vein, the pharmaceutical company Sanofi released important news. She plans an estimated investment of five million dollars for research and development of 45 clinical studies, in more than 240 research sites in Mexico.
Clinical trials to be carried out in Mexico
Most of the clinical studies are dedicated to the use of highly specialized therapies, for diseases such as: Asthma, Chronic Obstructive Pulmonary Disease (COPD), arthritis, systemic and cutaneous lupus erythematosus, atopic dermatitis, nodular prurigo, allergy, Covid-19, Pompe, Gaucher, MPS I, Fabry, Sjörgen’s syndrome, multiple sclerosis, diabetes, hypercholesterolemia, Myasthenia Gravis, Ulcerative Colitis, rhinosinusitis without nasal polyposis, dengue and influenza. Also in oncology, studies dedicated to breast cancer, lung, lymphoma and multiple myeloma are developed.
David Pinho, Country Lead of Sanofi Mexico
“Globally, Sanofi allocates almost $5.7 million euros to investment in Research and Development of new molecules or indications to treat immuno-inflammatory, oncological, neurological diseases, rare diseases, blood disorders and vaccines. Over the last 50 years, we have become a world leader in health care, with a wide range of patient-focused scientific discoveries.”
Sanofi is aware that investment in health is the most feasible path for the company’s social impact strategy, where the goal is to build a healthier and more resilient world by ensuring access to health care for all people.
For this reason, Sanofi focuses its mission with four business units specialized in various approaches to health:
- General Medicines, with solutions for the main public health problems in Mexico, such as cardiovascular diseases and diabetes.
- Immunizations, to prevent death or complications from preventable illnesses such as seasonal flu or influenza. childhood diseases, including polio, whooping cough, tetanus, hepatitis B, diphtheria, and haemophilus influenza.
- High Specialty, with unique therapies in its class that meet the needs of patients with complex conditions, such as atopic dermatitis or severe asthma, as well as multiple myeloma and rare diseases.
- Consumption, which makes it possible to put medicines and supplements within direct reach of people to promote health self careespecially digestive and respiratory.
“Sanofi Mexico’s commitment to public health has allowed us to protect hundreds of patients from diseases that are of priority importance to the country. We know that to the extent that we contribute to the empowerment of patients that allows them to assume care as a priority task, we will be able to close the path to diseases that are preventable by vaccination or controllable through adherence to treatment.”
He added that Sanofi Mexico is a Socially Responsible Company (ESR), certified by the Mexican Center for Philanthropy (Cemefi), which endorses the series of measures implemented at a local and global level to reduce the impact of our operations both in offices and in the three industrial sites in the State of Mexico. It also has certifications for the efficient use of natural resources, uses energy from renewable sources and promotes recycling and elimination of unnecessary consumables as much as possible.